Cargando…

Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial

BACKGROUND: Malignant pleural mesothelioma is a highly aggressive tumor associated with asbestos exposure. There are few effective treatment options for mesothelioma, and patients have a very poor prognosis. Mesothelioma has the potential to represent an appropriate disease to prevent because of its...

Descripción completa

Detalles Bibliográficos
Autores principales: Muti, Paola, Sacconi, Andrea, Pulito, Claudio, Orlandi, Giulia, Donzelli, Sara, Morrone, Aldo, Jiulian, James, Cox, Gerard P., Kolb, Martin, Pond, Gregory, Kavsak, Peter, Levine, Mark Norman, Blandino, Giovanni, Strano, Sabrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391647/
https://www.ncbi.nlm.nih.gov/pubmed/35987988
http://dx.doi.org/10.1186/s13046-022-02455-6
_version_ 1784770895306293248
author Muti, Paola
Sacconi, Andrea
Pulito, Claudio
Orlandi, Giulia
Donzelli, Sara
Morrone, Aldo
Jiulian, James
Cox, Gerard P.
Kolb, Martin
Pond, Gregory
Kavsak, Peter
Levine, Mark Norman
Blandino, Giovanni
Strano, Sabrina
author_facet Muti, Paola
Sacconi, Andrea
Pulito, Claudio
Orlandi, Giulia
Donzelli, Sara
Morrone, Aldo
Jiulian, James
Cox, Gerard P.
Kolb, Martin
Pond, Gregory
Kavsak, Peter
Levine, Mark Norman
Blandino, Giovanni
Strano, Sabrina
author_sort Muti, Paola
collection PubMed
description BACKGROUND: Malignant pleural mesothelioma is a highly aggressive tumor associated with asbestos exposure. There are few effective treatment options for mesothelioma, and patients have a very poor prognosis. Mesothelioma has the potential to represent an appropriate disease to prevent because of its strong association with asbestos exposure and the long latency from exposure to the disease on-set. METHODS: In the present study, we tested biological activity and toxicity of an artichoke freeze-dried extract (AWPC) as potential complementary preventive/early stage treatment agent for mesothelioma. This phase II clinical study then was conducted in 18 male-patients with evidence of radiographic characteristics related to asbestos exposure such as asbestosis or benign pleural disease as surrogate disease for mesothelioma clinical model. RESULTS: We investigate AWPC biological activity assessing its effect on mesothelin serum level, a glycoprotein with low expression in normal mesothelial cells and high expression in mesothelioma and asbestos related diseases. We also assess the AWPC effect on circulating miRNAs, as novel biomarkers of both cancer risk and response to therapeutic targets. While we found a small and not significant effect of AWPC on mesothelin serum levels, we observed that AWPC intake modulated 11 serum miRNAs related to gene-pathways connected to mesothelioma etiology and development. In terms of toxicity, we also did not observe any severe adverse effects associated to AWPC treatment, only gastro-intestinal symptoms were reported by five study participants. CONCLUSIONS: We observed an interesting AWPC effect on miRNAs which targets modulate mesothelioma development. New and much larger clinical studies based on follow-up of workers exposed to asbestos are needed to corroborate the role of AWPC in prevention and early treatment of mesothelioma. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02076672. Registered 03/03/2014. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02455-6.
format Online
Article
Text
id pubmed-9391647
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93916472022-08-21 Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial Muti, Paola Sacconi, Andrea Pulito, Claudio Orlandi, Giulia Donzelli, Sara Morrone, Aldo Jiulian, James Cox, Gerard P. Kolb, Martin Pond, Gregory Kavsak, Peter Levine, Mark Norman Blandino, Giovanni Strano, Sabrina J Exp Clin Cancer Res Research BACKGROUND: Malignant pleural mesothelioma is a highly aggressive tumor associated with asbestos exposure. There are few effective treatment options for mesothelioma, and patients have a very poor prognosis. Mesothelioma has the potential to represent an appropriate disease to prevent because of its strong association with asbestos exposure and the long latency from exposure to the disease on-set. METHODS: In the present study, we tested biological activity and toxicity of an artichoke freeze-dried extract (AWPC) as potential complementary preventive/early stage treatment agent for mesothelioma. This phase II clinical study then was conducted in 18 male-patients with evidence of radiographic characteristics related to asbestos exposure such as asbestosis or benign pleural disease as surrogate disease for mesothelioma clinical model. RESULTS: We investigate AWPC biological activity assessing its effect on mesothelin serum level, a glycoprotein with low expression in normal mesothelial cells and high expression in mesothelioma and asbestos related diseases. We also assess the AWPC effect on circulating miRNAs, as novel biomarkers of both cancer risk and response to therapeutic targets. While we found a small and not significant effect of AWPC on mesothelin serum levels, we observed that AWPC intake modulated 11 serum miRNAs related to gene-pathways connected to mesothelioma etiology and development. In terms of toxicity, we also did not observe any severe adverse effects associated to AWPC treatment, only gastro-intestinal symptoms were reported by five study participants. CONCLUSIONS: We observed an interesting AWPC effect on miRNAs which targets modulate mesothelioma development. New and much larger clinical studies based on follow-up of workers exposed to asbestos are needed to corroborate the role of AWPC in prevention and early treatment of mesothelioma. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02076672. Registered 03/03/2014. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02455-6. BioMed Central 2022-08-20 /pmc/articles/PMC9391647/ /pubmed/35987988 http://dx.doi.org/10.1186/s13046-022-02455-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Muti, Paola
Sacconi, Andrea
Pulito, Claudio
Orlandi, Giulia
Donzelli, Sara
Morrone, Aldo
Jiulian, James
Cox, Gerard P.
Kolb, Martin
Pond, Gregory
Kavsak, Peter
Levine, Mark Norman
Blandino, Giovanni
Strano, Sabrina
Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
title Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
title_full Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
title_fullStr Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
title_full_unstemmed Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
title_short Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial
title_sort artichoke phytocomplex modulates serum micrornas in patients exposed to asbestos: a first step of a phase ii clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391647/
https://www.ncbi.nlm.nih.gov/pubmed/35987988
http://dx.doi.org/10.1186/s13046-022-02455-6
work_keys_str_mv AT mutipaola artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT sacconiandrea artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT pulitoclaudio artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT orlandigiulia artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT donzellisara artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT morronealdo artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT jiulianjames artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT coxgerardp artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT kolbmartin artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT pondgregory artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT kavsakpeter artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT levinemarknorman artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT blandinogiovanni artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial
AT stranosabrina artichokephytocomplexmodulatesserummicrornasinpatientsexposedtoasbestosafirststepofaphaseiiclinicaltrial